New Delhi, June 7: The All India Institute of Medical Sciences (AIIMS), Delhi, will start screening children for clinical trials of indigenous home-grown COVID-19 vaccine, Bharat Biotech's Covaxin, from Monday, sources said.

AIIMS, Delhi will be starting clinical trials after AIIMS Patna which started the trials recently on children aged between 12 and 18 years old. Clinical Trials of Niclosamide, Repurposed Drug For COVID-19 Treatment, Initiated by CSIR India & Laxai Life Sciences.

After getting permission from the Drugs Controller General of India (DCGI), AIIMS, Delhi is now starting the screening for clinical trials before starting the trials.

To grant the permission of trials, DCGI's approval was followed by a recommendation on May 12 by a Subject Expert Committee (SEC).

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)